A meta-analysis focusing on cancer treatment-related myeloid neoplasm revealed that cancer treatment-selected for clones with mutations in the DNA damage response (DDR) genes TP53, PPM1D, and CHEK2, which were significantly enriched in therapy-related myeloid neoplasm (tMN). The gene discussed is TP53; the disease is myeloid neoplasm.